Effect of Vibrotactile Stimulation in Lateral Epicondylitis
Launched by MEDIPOL UNIVERSITY · Nov 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment method called vibrotactile stimulation for people with lateral epicondylitis, commonly known as tennis elbow. The goal is to see if this type of vibration therapy can help reduce pain, improve sensation, and enhance the overall function of the affected arm. The trial is currently recruiting participants aged 18 to 65 who have been diagnosed with lateral epicondylitis. However, individuals who have had elbow surgery, or who have certain medical conditions affecting their arm or nervous system, are not eligible to join.
If you participate in this study, you can expect to receive vibrotactile stimulation during your treatment sessions. The trial aims to understand how this therapy can impact your pain and ability to use your arm. It's a great opportunity to contribute to research that could help others with similar conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being between 18-65 years of age
- • Patients diagnosed with lateral epicondylitis
- Exclusion Criteria:
- • Having had elbow surgery
- • Having a history of congenital or acquired orthopedic, neurological, or rheumatological conditions affecting the upper limb
- • Having received any conservative treatment for the diagnosis of lateral epicondylitis
About Medipol University
Medipol University is a leading academic institution dedicated to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices. Leveraging state-of-the-art facilities and a team of experienced researchers and healthcare professionals, Medipol University is committed to contributing to the global medical community through ethical research and the development of novel therapeutic strategies. The institution fosters an environment of academic excellence and integrity, ensuring that all trials adhere to the highest standards of safety and efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported